Astron (544628)

Score breakdown: P/E: 3/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• P/E of 7.40 suggests a potentially low valuation if the reported earnings are genuine and sustainable.
• ROCE of 25.21% indicates efficient use of capital on an operating level.
• Packaged foods is a simple, understandable business with recurring consumer demand.
• Tiny ₹17 Cr market cap offers high optionality if the company executes and discloses better.

Concerns

• Latest quarter sales and net profit are ₹0 Cr, suggesting either collapsed operations or unreliable data.
• Zero sales growth, zero profit growth, and zero dividend yield provide no compounding or income support.
• Piotroski F-Score of 3/9 points to weak financial health and a higher risk profile.
• Missing book value, debt/equity, promoter holding, and 52-week range prevent a proper margin-of-safety calculation.

AI Analysis

At ₹19.87, Astron is a ₹17 crore micro-cap in packaged foods. The P/E of 7.40 looks like a Graham-style bargain, but a low multiple is only meaningful if the earnings behind it are real and repeatable. The latest quarter shows sales of ₹0 crore and net profit of ₹0 crore; that is a major red flag or a serious data gap. Zero sales growth and zero profit growth give me no evidence of a compounding machine. The reported ROCE of 25.21% catches my eye—it suggests the existing capital base is being used efficiently—but I cannot calculate a margin of safety without book value, debt-to-equity, or promoter holding data. The Piotroski F-Score of 3/9 reinforces my caution: this is a weak financial-health score. No dividend means I earn nothing while I wait, and at ₹17 crore market cap, liquidity is likely to be poor. In packaged foods, I want brand strength, distribution advantage, or pricing power; I see no evidence of any moat here. Graham would say to buy with enough margin of safety; with so many critical numbers missing, I cannot intelligently value the business. This could be a slow grower at a cheap multiple, but the absence of transparency and the zero quarterly numbers make it a pass. I would need audited financials, a clean quarterly trajectory, and proof that the zero revenue is a reporting error rather than a collapsed business. If those facts emerge, I would gladly take another look at this price.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer